Pelvic Inflammatory Disease (PID) Treatment Market Size, Share and Global Trend By Drug Class (Quinolones, Tetracycline, Beta-lactam, Nitroimidazoles), By Type (Subacute Pelvic Inflammatory Disease, Chronic Pelvic Inflammatory Disease,Others), By Route of Administration (Oral, Intravenous, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) Regional Forecast, 2024-2032

Pelvic Inflammatory Disease (PID) is a disease which is essentially the infection of the female reproductive organs and is generally caused due to the spread of the bacteria from the vagina and the cervix. In 75% to 90% of the incidences, the disease is caused by Chlamydia trachomatis or Neisseria gonorrhoeae and in many of the cases, the presence of multiple bacteria is found. According to the U.S. Department of Health and Human Services, the disease is common and affects more than 1 million individuals annually in the U.S. The primary course of treatment for the Pelvic Inflammatory Disease (PID) is through the administration of antibiotics and in some rarer cases with severe complications, the physicians may suggest surgery.

Most of the treatment is conducted through the intravenous/ parenteral and the oral or intramuscular route, with a variety of antibiotics equipped with treating various bacterial infections. Since most of the treatment is undertaken by antibiotics which are utilized for the treatment of other diseases too, a number of key pharmaceutical market leaders are present. A number of clinical trials are being undertaken for the treatment of pelvic inflammatory disease (PID), which includes antibiotics such as ceftriaxone, doxycycline, and metronidazole. Bayer AG has initiated a clinical trial in 2018 of a new molecular entity (BAY 1834845) for the treatment of Pelvic Inflammatory Disease (PID). 

Pelvic Inflammatory Disease (PID) is a common disease among the females, with an estimated 1 million new diagnoses every year in the U.S. Thus, the number of individuals suffering from this disorder is expected to rise due to increasing global population coupled with increasing awareness about the disease in the emerging markets. These have led to many key market players such as Bayer AG to focus on the research & development of new treatment drugs for the disease or direct focus towards increasing the efficiency of the existing and approved drugs. 

The factor that is expected to inhibit the growth of the market is the stringent regulatory scenario and the associated regulatory hurdles that the companies have to undergo before receiving the regulatory approval. This stringent and convoluted process may deter many of the applicants undergoing the product development process for the marketing and commercialization approvals for their products. Some of the associated side effects of the drugs may also deter the growth of the market.

 Key Players Covered 

Some of the major companies that are present in the global pelvic inflammatory disease (PID) treatment market are F. Hoffmann-La Roche, Pfizer Inc., Lupin, Cambrex Corporation, Cipla Inc., Bayer AG, and DAIICHI SANKYO COMPANY, LIMITED. and other players. 

 SEGMENTATION

At present, subacute pelvic inflammatory disease (PID) accounts for the largest proportion of the market by type and by geography, North America has the highest share of the pelvic inflammatory disease (PID) due to the high rate of occurrence of the disease, combined with the access to advanced treatment options and increasing awareness of the disease due to increasing demand for preventive medical care. 

Key Insights 

• Prevalence of pelvic inflammatory disease (PID) by key countries
• Advancements in the research & development of treatment options
• Overview of advances in novel therapeutics
• New product launches  

Regional Analysis 

The global pelvic inflammatory disease (PID) treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America followed by Europe are the two largest markets for pelvic inflammatory disease (PID) treatment at present and they are expected to account for a large proportion of the market in the forecast period as well. North America has a high rate of occurrence of the disease and this has led to a greater demand for the treatment options for the disease. In January 2019, the Food and Drug Administration (FDA) permitted the marketing of the first test to aid in the diagnosis of pelvic inflammatory disorder (PID). In the Asia Pacific region, Japan is expected to provide the largest market opportunity, with approximately 468,136 individuals out of its 127 million population, having already suffered from this disease or currently suffering from. 

Key Industry Developments

• In January 2019, the Food and Drug Administration (FDA) for the first time gave the approval for the marketing of the first ever test to be utilized for the diagnosis of pelvic inflammatory disease (PID) called the Aptima Mycoplasma genitalium Assay.
• Bayer AG is undertaking the clinical trial of a new molecular entity to be utilised in the treatment of the pelvic inflammatory disease (PID) called BAY1834845, which is currently in Phase 1 of the clinical trial process, as of December 2018.
• A Chinese pharmaceutical company called the Jiangsu Hansoh Pharmaceutical Co., Ltd. is undertaking clinical trials to test for the safety and efficacy of morinidazole in the women diagnosed with pelvic inflammatory disease (PID) and is currently in Phase 4 of the clinical trials, as of January 2018.